Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011551 (depersonalization)
 1,117 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An open clinical study was conducted with carpipramine in 100 hospitalized subjects presenting various mental disorders. The therapeutic results on symptoms were assessed both as a whole and with the help of a rating scale. Doses varied from 50 to 400 mg per day. Carpipramine seems to be particularly efficient on schizophrenias, 66 cases of which were tested. The best results were observed in hebephrenic forms and depressive syndroms during the illness; in these indications, carpipramine exerts a clear psychomotor stimulating activity which is useful in decreasing indifference, apathy and ideomotor slowness. Schizophrenias with paranoid delusions or depersonalization anxiety tend to be somehow aggravated. Carpipramine does not seem to be a true antidepressant despite its desinhibitory properties. The compound proves useful in deficits of the psychomotor tone such as those occuring in psychasthenia or the deficit syndrom which follows withdrawal from opiates. Clinical and biological tolerances seem to be excellent and extrapyramidal side effects are exceptional. Carpipramine may be considered as a strongly desinhibitory neuroleptic agent which bears some resemblance to antidepressants because of its psychoanaleptic effect. The authors raise the question of possible antipsychotic properties in higher doses in relation to pharmacological data and a bipolar, antipsychotic and predominantly desinhibitory, therapeutic action.
 ...
PMID:[A new psychotropic drug: carpipramine, intermediate compound between 2 therapeutic classes]. 1 31

Description of psychasthenia by P. Janet (1903) sets up at the end of a double reflection, with on the one hand a theorization of asthenia, the notion of which already occupied the medical concepts of the 18th and 19th centuries, and on the other hand a progressive attribution of neurosis to the psychiatric field. Its clinical characteristics (feelings of non-fulfillment in action and emotion, experiences of oddness and depersonalization, obsessions, phobias...) makes psychasthenia a fully-fledged illness, the psychopathological organization of which results from a decrease of psychological tension and from a loss of reality function. Since P. Janet, the term of psychasthenia has not ceased to be used, although its etiopathological references blurred behind the psychoanalytic work, and it is usually synonymous with obsessional neurosis, even with obsessional personality. Description of psychasthenia appears in these rubrics of the DSM III, even though the term itself is ignored.
 ...
PMID:[Psychasthenia: history and evolution of the P. Janet concept]. 784 50